Business Samsung joins hands with GRAIL to bring the cancer early detection test to Asia
By Diplomacy Journal Lee Kap-soo Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), announced on Oct. 17 that they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL’s GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of $70.05 per share of common stock. “Guided by its commitment to advancing next-generation bio-technologies and improving quality of life